Cresco Labs (CRLBF) Other Non-Current Liabilities (2019 - 2026)
Cresco Labs' (CRLBF) quarterly Other Non-Current Liabilities came in at $184.9 million in Q1 2026, up 36.15% YoY from $135.8 million in Q1 2025, and up 7.83% on a QoQ basis from $171.5 million in Q4 2025.
Cresco Labs (CRLBF) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 8 years of Other Non-Current Liabilities data on file, last reported at $184.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 36.15% year-over-year to $184.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.9 million (up 36.15% YoY) and the FY2025 annual result came in at $171.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities advanced to $184.9 million in Q1 2026, from $171.5 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $184.9 million in Q1 2026 to a low of $7.0 million in Q1 2022.
- A 5-year average of $97.2 million and a median of $136.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities fell 18.14% — and 2025, when it jumped 522.14%.
- Tracing CRLBF's Other Non-Current Liabilities over 5 years: stood at $12.9 million in 2022, then surged by 56.67% to $20.2 million in 2023, then surged by 658.94% to $153.4 million in 2024, then grew by 11.79% to $171.5 million in 2025, then gained by 7.83% to $184.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $184.9 million (Q1 2026), $171.5 million (Q4 2025), and $165.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Cresco Labs | 292.94 Mn | 228.83 Mn | 86.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184.91 Mn |
| Dec 31, 2025 | 171.47 Mn |
| Sep 30, 2025 | 165.16 Mn |
| Jun 30, 2025 | 150.54 Mn |
| Mar 31, 2025 | 135.81 Mn |
| Sep 30, 2024 | 153.40 Mn |
| Jun 30, 2024 | 136.64 Mn |
| Mar 31, 2024 | 21.83 Mn |
| Dec 31, 2023 | 20.21 Mn |
| Dec 31, 2022 | 12.90 Mn |
| Jun 30, 2022 | 7.01 Mn |
| Mar 31, 2022 | 7.01 Mn |
| Dec 31, 2021 | 7.00 Mn |
| Sep 30, 2021 | 7.04 Mn |
| Mar 31, 2021 | 8.56 Mn |
| Dec 31, 2020 | 8.56 Mn |
| Dec 31, 2019 | 15.24 Mn |